REG - J.P. Morgan Sec PLC Takeda Pharma.Co.Ltd - Stabilisation Notice

Takeda Pharmaceutical CoAnnouncement

16/11/2018 16:50

RNS Number : 6759H
J.P. Morgan Securities PLC.
16 November 2018
 


16th November 2018
Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.
Takeda Pharmaceutical Company Limited
Post-stabilisation Period Announcement
Further to the pre-stabilisation period announcement 15 November        2018, J.P. Morgan Securities plc, (contact: Emma Lovett 0207 134 2468) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014) or the rules of the Financial Conduct Authority) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.



Issuer:


Takeda Pharmaceutical Company Limited




Guarantor (if any):








Aggregate nominal amount:


EUR 7.5bn




Description:


EUR 2yr FRN, 2yr FXD, 4yr FRN, 4yr FXD, 8yr FXD and 12yr FXD
Senior, Unsecured, 144a / Reg S
Singapore Listing / NY Law / €100k+1k /




Stabilisation Manager(s):


J.P. Morgan Securities plc (Stabilisation coordinator)
 




Offer price:


2yr FRN 100%, 2yr FXD 99.907%, 4yr FRN 100%, 4yr FXD 99.612%, 8yr FXD 99.862%, 12yr FXD 99.464%
 








 



 
This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction
This announcement is not an offer of securities for sale into the United States. The securities referred to above have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There has not been and will not be a public offer of the securities in the United States




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
STAEAKFKFLLPFFF